Respiratory Syncytial Virus (RSV)

Wastewater testing rose in prominence during the COVID-19 pandemic.

Interest in getting the newly approved RSV vaccine varies by factors such as age and underlying health status, according to a survey of older US adults.

FDA's approval is for use of the vaccine, called Abrysvo, at 32 to 36 weeks gestational age of pregnancy.

The survey findings come ahead of a future recommendation for pregnant women as a strategy to protect babies.

The CDC is recommending a dose of the monoclonal antibody nirsevimab to protect against severe illness caused by RSV.

In the small phase 1 study, children received a single dose of the live attenuated nasal vaccine.

The rates the researchers saw could serve as a baseline for gauging whether coinfections rates are shrinking or growing.

Twelve fur farms in Finland have now been affected by H5N1 avian flu outbreaks.

The drug is indicated for babies entering their first RSV season and for kids up to 2 years old who remain vulnerable in their second season.